

SEP 24 2001

**GE Medical Systems**

Page 1 of 2

General Electric Company
P.O. Box 414, Milwaukee, WI 53201**510(k) Summary**

This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR Part 807.92(c).

Submitter: GE Medical Systems
PO Box 414
Milwaukee, WI 53201

Contact Person: Larry A. Kroger Ph.D.
Manager, Regulatory Programs

Telephone: 262- 544-3894

Fax: 262- 544-3863

Date Prepared: August 30, 2001

Device Name:

GE Signa ASSET Imaging Option
Magnetic Resonance Diagnostic System, 21 CFR 892.1000, 90-LNH

Marketed Device:

The Signa ASSET Imaging Option is substantially equivalent to the Array Processor subsystem and reconstruction techniques of the currently marketed Signa 1.5T TwinSpeed Magnetic Resonance System (K012200), Signa VH/i MR System (K990550; K003575; and K006313) and Signa HFO/i MR System (K992746).

Device Description:

ASSET (Array Spatial Sensitivity Encoding Technique) is an image reconstruction technique used in conjunction with phased array coils in which the number of phase encode steps is reduced by increasing the distance between steps, or equivalently, by reducing the field of view. Aliasing or wrapping caused by the object extending outside the reduced field of view is eliminated using knowledge of the B1 fields of the coils.

Indications for Use:

The Signa Magnetic Resonance System is a whole body scanner. The Signa Magnetic Resonance System is indicated for use as a diagnostic imaging device to produce transverse, sagittal, coronal and oblique images of the internal structures of the head or body. The images produced by the Signa Magnetic Resonance System reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T1), spin-spin relaxation time (T2) and flow. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.



Comparison with Predicate Device:

It is the opinion of GE Medical Systems that the ASSET Imaging Option is substantially equivalent to the Array Processor subsystem and Reconstruction Techniques used in the currently cleared Signa 1.5T TwinSpeed Magnetic Resonance System (K012200), Signa VH/i MR System (K990550; K003575; and K006313) and Signa HFO/i MR System (K992746). It has the same intended use, and operating modes as the predicate devices.

Summary of Studies:

The ASSET Imaging Option was developed in conformance with design control requirements as specified in 21 C.F.R. 820.30. Software hazard analysis and verification test procedures were completed. Evaluation testing was done to verify the performance of the option.

Conclusion:

It is the opinion of GE that the ASSET Imaging option does not result in any new potential hazards.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

SEP 24 2001

Larry Kroger, Ph.D.
Regulatory Programs Manager
GE Medical Systems
General Electric Company
P.O. Box 414
MILWAUKEE WI 53201

Re: K012970
Trade/Device Name: GE Signa Asset Imaging Option
for MRI
Regulation Number: 21 CFR 892.1000
Regulation Name: Magnetic Resonance Diagnostic Device
Regulatory Class: II
Product Code: 90 LNH
Dated: August 30, 2001
Received: September 4, 2001

Dear Dr. Kroger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): K012970

Device Name: Signa ASSET Imaging Option

Indications For Use:

The Signa Magnetic Resonance System is a whole body scanner. The Signa Magnetic Resonance System is indicated for use as a diagnostic imaging device to produce transverse, sagittal, coronal and oblique images of the internal structures of the head or body. The images produced by the Signa Magnetic Resonance System reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density, spin-lattice relaxation time (T1), spin-spin relaxation time (T2) and flow. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE

IF NEEDED)

Nancy C. Brogdon

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR Over-The-Counter Use _____